Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotac PharmaceuticalsNSE:SOTAC 49 EV-to-EBITDA is 7.77 as of Sep. 04, 2026, which is 55% below its 10-year median of 17.10. GuruFocus rates NSE:SOTAC with a GF Score™ of 49/100 and a GF Value™ of ₹142.60 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 726 Drug Manufacturers companies, Sotac Pharmaceuticals ranks better than 71.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sotac Pharmaceuticals's enterprise value is ₹1,416.2 Mil.
Sotac Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹182.3 Mil. Therefore, Sotac Pharmaceuticals's EV-to-EBITDA for today is 7.77.
The historical rank and industry rank for Sotac Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:SOTAC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.77 Med: 17.1 Max: 24.7
Current: 7.77
During the past 7 years, the highest EV-to-EBITDA of Sotac Pharmaceuticals was 24.70. The lowest was 7.77. And the median was 17.10.
NSE:SOTAC's EV-to-EBITDA is ranked better than 71.9% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs NSE:SOTAC: 7.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sotac Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Sotac Pharmaceuticals's share price for today is ₹90.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sotac Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Sotac Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sotac Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sotac Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotac Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sotac Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sotac Pharmaceuticals's EV-to-EBITDA falls into.
Sotac Pharmaceuticals's current Enterprise Value is ₹1,416.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sotac Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹182.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotac Pharmaceuticals (NSE:SOTAC) has a EV-to-EBITDA of 7.77 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sotac Pharmaceuticals. This is 55% below median its historical median of 17.10. Over the past decade, Sotac Pharmaceuticals' EV-to-EBITDA has ranged from 7.77 to 24.70. According to the industry distribution chart, Sotac Pharmaceuticals ranks #204 out of 726 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Sotac Pharmaceuticals' EV-to-EBITDA too high?
Sotac Pharmaceuticals' current EV-to-EBITDA of 7.77 is 55% below median its 10-year median of 17.10. Over the past 10 years, this metric has ranged from a low of 7.77 to a high of 24.70. The Drug Manufacturers industry median EV-to-EBITDA is 13.55. Sotac Pharmaceuticals' value of 7.77 is 42.7% below this industry median. Based on the distribution chart, Sotac Pharmaceuticals ranks #204 out of 726 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sotac Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sotac Pharmaceuticals ranks #204 out of 726 companies for EV-to-EBITDA. This puts Sotac Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBITDA is 13.55. Sotac Pharmaceuticals' value of 7.77 is 42.7% below this benchmark. Historically, Sotac Pharmaceuticals' own EV-to-EBITDA has ranged from 7.77 to 24.70 over the past decade. While the company's 10-year median is 17.10 vs. the industry median of 13.55, Sotac Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.55, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotac Pharmaceuticals's current EV-to-EBITDA of 7.77 is 42.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sotac Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotac Pharmaceuticals's current EV-to-EBITDA is 7.77, which is 55% below median its own 10-year median of 17.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹142.60, compared to a current price of ₹90.05 — trading 36.9% below its estimated fair value. The current EV-to-EBITDA is 7.77, which is 55% below median its 10-year median of 17.10 and 42.7% below the Drug Manufacturers industry median of 13.55. Sotac Pharmaceuticals' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current EV-to-EBITDA is 7.77 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹90.05 is trading 36.9% below its estimated GF Value™ of ₹142.60.
GuruFocus considers Sotac Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:SOTAC:
EV-to-EBITDA: 7.77 (55% below median its 10-year median of 17.10)
GF Value™: ₹142.60 vs. price of ₹90.05 (36.9% below fair value)
Industry Position: 42.7% below the Drug Manufacturers median (#204 of 726)
No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
49GF Score
Get the complete analysis for NSE:SOTAC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOTAC has been successfully added to your 
